GALDERMA INDIA PRIVATE LIMITED

The U.S. FDA has approved Restylane Lyft with Lidocaine for chin augmentation in patients over 21 with mild-to-moderate chin retrusion, making it the only hyaluronic acid injectable approved for multiple facial areas including midface, hands, and now chin.

Sol-Gel Technologies has completed patient enrollment for its pivotal Phase 3 clinical trial of SGT-610, a topical hedgehog pathway inhibitor for preventing basal cell carcinomas in Gorlin syndrome patients.

Galderma's phase IV clinical trial demonstrates sustained efficacy of combined Sculptra and Restylane Lyft or Contour treatment for facial volume loss associated with GLP-1 receptor agonist medications over nine months.

Galderma has initiated two phase II clinical trials investigating nemolizumab, an IL-31 receptor alpha-targeting monoclonal antibody, for treating systemic sclerosis and chronic pruritus of unknown origin.

New two-year data from the ARCADIA long-term extension study demonstrate that Nemluvio (nemolizumab) maintains sustained and increased improvements in itch, skin lesions, sleep, and quality of life in patients with moderate-to-severe atopic dermatitis.

• Sol-Gel Technologies has entered into a $16 million agreement with Mayne Pharma for the sale and exclusive license of U.S. rights to dermatology products EPSOLAY and TWYNEO, extending the company's cash runway into Q1 2027. • The transaction allows Sol-Gel to focus resources on its promising SGT-610 program for Gorlin syndrome, which has completed 80% patient recruitment for Phase III trials with top-line results expected in Q4 2026. • Based on recent market research, Sol-Gel estimates SGT-610's U.S. market potential between $400-500 million annually as the first potential preventative treatment for basal cell carcinomas in Gorlin syndrome patients.

Phase IIIb RELAX trial data demonstrates rapid onset of aesthetic improvement with Relfydess (RelabotulinumtoxinA) for frown lines, with 40% of subjects reporting improvement on Day 1.

The FDA has approved Neurocrine's Crenessity as an adjunct therapy for classic congenital adrenal hyperplasia, offering patients a way to reduce steroid treatment burden.

The FDA has approved Nemluvio (nemolizumab) for moderate-to-severe atopic dermatitis in patients 12 years and older when topical treatments are inadequate.

• Newly published results in JAMA Dermatology demonstrate nemolizumab monotherapy significantly improved itch intensity and skin lesions in patients with moderate-to-severe prurigo nodularis compared to placebo. • The OLYMPIA 1 trial showed rapid response as early as Week 4, with over six times more nemolizumab-treated patients achieving itch response and twenty times more reaching an itch-free or nearly itch-free state compared to placebo. • Based on the OLYMPIA clinical trial program, nemolizumab (Nemluvio®) received FDA approval for adult prurigo nodularis in August 2024, with additional regulatory reviews ongoing worldwide.